Cargando…
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity
[Image: see text] We report on the design, synthesis, and biological evaluation of a series of nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists with improved in vitro and in vivo adjuvant properties. We identified two promising compounds: 68, a potent...
Autores principales: | Guzelj, Samo, Nabergoj, Sanja, Gobec, Martina, Pajk, Stane, Klančič, Veronika, Slütter, Bram, Frkanec, Ruža, Štimac, Adela, Šket, Primož, Plavec, Janez, Mlinarič-Raščan, Irena, Jakopin, Žiga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279416/ https://www.ncbi.nlm.nih.gov/pubmed/34043358 http://dx.doi.org/10.1021/acs.jmedchem.1c00644 |
Ejemplares similares
-
Discovery
of Desmuramylpeptide NOD2 Agonists with
Single-Digit Nanomolar Potency
por: Guzelj, Samo, et al.
Publicado: (2022) -
Covalently
Conjugated NOD2/TLR7 Agonists Are Potent
and Versatile Immune Potentiators
por: Guzelj, Samo, et al.
Publicado: (2022) -
Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity
por: Guzelj, Samo, et al.
Publicado: (2022) -
Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy
por: Nabergoj, Sanja, et al.
Publicado: (2018) -
Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening
por: Guzelj, Samo, et al.
Publicado: (2022)